Wegovy口服片在美国上市后的前四天内开出了3071张处方

Core Insights - The core insight of the article is that Novo Nordisk's weight loss drug Wegovy has shown strong initial demand in the U.S. market, with 3,071 prescriptions written in the first four days post-launch, indicating a potential competitive advantage over rivals like Eli Lilly [1] Group 1: Market Performance - Wegovy's oral tablet has achieved 3,071 prescriptions within the first four days of its U.S. launch, reflecting significant initial uptake [1] - The data shared by analysts only accounts for retail channel prescriptions and does not include those dispensed through Novo Nordisk's own NovoCare Pharmacy online channel, suggesting that the actual number of prescriptions could be higher [1] Group 2: Competitive Landscape - Investors are closely monitoring Novo Nordisk's ability to maintain its first-mover advantage in a highly competitive weight loss drug market [1] - The competitive dynamics are highlighted by the presence of other players like Eli Lilly, emphasizing the importance of Wegovy's market performance in sustaining its lead [1]